This product was developed by the Providence St. Peter Family Medicine Residency Program at Providence St. Peter Family Medicine in Olympia, WA. Support for this product was provided by a grant from the Robert Wood Johnson Foundation® in Princeton, New Jersey.
DIABETES FOR THE PRIMARY CARE PROVIDER...WHAT WE CAN DO AS PCP’S...PART 1

DEVIN SAWYER, MD
SEPTEMBER 22, 2005
What you will be seeing in practice

BMJ, 2003
So who is better? FP’s or Endo

• Specialist
  – <10%
  – Give better foot care
  – More likely to use insulin
  – Use newer and more expensive meds
  – Outcomes are better when in an organized program

• Generalist
  – >90%
  – More likely to have other health issues addressed
  – Less likely than non-DM (ie mammograms)
  – Less likely to work in a Chronic Care Program

Only 9% of patients are at goal for HBA1c, BP, Lipids, ASA, and Screening

Medical Outcomes Study found little advantage between Edocrine and FP’s

Overall functional status at 4 yrs and mortality at 7 years was the same…but
45 year old
BMI = 33
Great-grandmother with DMII
Loves the couch
Wants to know if he needs to be screened for DM
Should we screen?

- DM II is a major public health affecting 8% of the population
- There is a long asymptomatic period
- There is an available and inexpensive test
- DM II is a treatable condition
- Treatment can result in prevention/delay of complications
- Jury is out as to whether it is cost effective or not (common sense says it does make sense, but our track record for tx DM effectively isn’t good)
So who and when?

- Everyone? Or be selective?

ADA recommends:
- 45 or older
- BMI over 25
- FMHx (first degree relative)
- Habitual physical inactivity
- High risk ethnic or racial group
- H/O gestational diabetes
- H/O delivering a baby over 9 lbs
- Hypertension (140/90)
- Dyslipidemia
- PCO
- Known vascular disease
...so how?

- Fasting BS (ADA)
- The IHOP challenge (WHO)...
- In 2003 an *international expert committee* issued a report revising recommendations- FBS X2

**FBS = 105**

So what do you tell him?
IFG

• FBS between 100 and 125
• NOT at risk for developing microvascular disease, but is at risk for MACROvascular disease and going on to develop DM II
• Lipids, BP, smoking, obesity... become important issues to talk about
• 15-20% of population have IFG
• Once IFG, screen every year there after
• IS REVERSABLE (or at least DM can be delayed)
Diabetes Prevention Trial

N Engl J Med, 2002; 346: 393
10 years later…

• 55 yo “let myself go”
  – known DMII
  – Obesity
  – still smoking
  – Hypertension
  – …wants to “start over”

• Where is he heading?
• What do you do?
Ghost of Christmas Future…
Start small...don’t go overboard

- HBA1c
- BP
- Lipids
- Weight
- Look for end organ damage (microvascular disease)
- Screen for macrovascular disease
- BS home monitoring
- DM meds
- HTN meds
- ASA
- Referrals
- Immunizations
- Screen for depression
- Smoking cessation counselling
- Diet
- Exercise

Where do you start? Let the patient guide you
He wants to talk DM Meds…

- Increase insulin release
- Increase insulin responsiveness
- Modify intestinal absorption of carbs
- Give exogenous insulin
Drugs that increase insulin secretion

• Sulfonylureas (glyburide, glipizide)
  – Oldest class of drugs
  – Can expect a HBA1c 1-2% reduction
  – “Bridge to insulin”
  – Watch for hypoglycemia
  – Cheap
  – Effectiveness wanes over time
  – Be careful with CRI/CRF
  – 2.5mg to 10mg daily or BID
Drugs that increase insulin secretion

- Meglitinides (Starlix, Prandin)
  - TID dosing before meals
  - No renal clearance
  - Otherwise same as Sulfonylureas
  - Much more expensive
  - Not used very often
Drugs that improve insulin action

• Biguanides (Metformin)
  – Decrease liver glucose output, increase peripheral insulin sensitivity
  – Can improve lipid profile
  – Patients can lose weight (or maintain)!!! In UKPDS:
    • only group that didn’t gain weight
    • Obese patients were less likely to die (decreased risk of aggregate diabetes related endpoint and all-cause mortality)
  – BID (500 or 850) with meals, 2550mg max
  – Be careful with RI
  – Getting cheaper
  – No hypoglycemia (but…)
Drugs that improve insulin action

- Thiazolidinediones (rosiglitazone- *Avandia*, and pioglitazone- *Actos*)
  - Act by increasing glucose utilization and decreasing glucose production
  - Mechanism not well understood
  - Best when used in combination, but be careful with insulin
  - Not as good monotherapy agents
  - Associated with weight gain
  - Expensive
  - Fluid retention- can make CHF worse
Drugs that modify the intestinal absorption

- The alpha-glucosidase inhibitors (Acarbose and Miglitol) and lipase inhibitors
  - Work best to lower PP BS, and HA1c reduction proportional to weight loss
  - May help lipid profile
  - Likely to cause flatulence (73%) and diarrhea
  - 16-20% of patients were still taking med after 1 year with a further 50% of those who stopped in year 2
  - Can expect a HBA1c reduction of 0.5 to 1%
  - 50 to 100mg with 1st bite of each meal
Insulin therapy

• Usually after combination orals are no longer effective
• Studies suggest we probably don’t start soon enough (patient/provider fear of insulin)
• Think of insulin earlier in the young adult who may have presented with wt loss or in DKA (late type I or type 3)
• Dosing based on FBS and weight (markers for insulin resistance)
Insulin therapy

<table>
<thead>
<tr>
<th>Insulin Type</th>
<th>Onset</th>
<th>Peak</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lantus</td>
<td>2 hrs</td>
<td>no peak</td>
<td>24 hrs</td>
</tr>
<tr>
<td>Ultalente</td>
<td>4 hrs</td>
<td>10-20 hrs</td>
<td>12-20 hrs</td>
</tr>
<tr>
<td>NPH/Lente</td>
<td>2 hrs</td>
<td>6-10 hrs</td>
<td>18-24 hrs</td>
</tr>
<tr>
<td>Regular</td>
<td>30 mins</td>
<td>2-4 hrs</td>
<td>5-8 hrs</td>
</tr>
<tr>
<td>Novalog, Humalog</td>
<td>5-15 mins</td>
<td>45-75 mins</td>
<td>2-4 hrs</td>
</tr>
</tbody>
</table>

---

**Initial Insulin Dose in Patients with Type 2 Diabetes According to Fasting Blood Glucose (FBG) and Degree of Obesity†**

<table>
<thead>
<tr>
<th>FBG, mg/dL</th>
<th>FBG, mmol/L</th>
<th>Percent ideal body weight</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>100</td>
</tr>
<tr>
<td>108</td>
<td>6</td>
<td>6</td>
</tr>
<tr>
<td>144</td>
<td>8</td>
<td>10</td>
</tr>
<tr>
<td>180</td>
<td>10</td>
<td>14</td>
</tr>
<tr>
<td>216</td>
<td>12</td>
<td>18</td>
</tr>
<tr>
<td>≥252</td>
<td>≥14</td>
<td>22</td>
</tr>
</tbody>
</table>

†Adapted from Holman, RR; Turner, RC, Diabetic Med 1985; 2:45.
Intensive glycemic control prevents microvascular disease in patients with type 2 diabetes. Kaplan-Meier plots of aggregate endpoints of microvascular disease in patients with type 2 diabetes mellitus in the United Kingdom Prospective Diabetes Study who were randomly assigned to receive either intensive therapy with a sulfonylurea or insulin or to conventional treatment with diet; drugs were added if the patients had hyperglycemic symptoms or fasting blood glucose concentrations greater than 270 mg/dL (15 mmol/L). Intensive therapy was associated with a 25 percent reduction (P = 0.01) in the development of microvascular disease, which was defined as renal failure, death from renal failure, retinal photocoagulation, or vitreous hemorrhage. (Data from UK Prospective Diabetes Study, Lancet 1998; 352:837.)

- Patients gain weight
- Issues with adherence
- Problems with hypoglycemia
- Look for the motivated patient
Benefits of lowering BS?

• Risk reduction from micro-vascular complications (DCCT and UKPDS)
  – Nephropathy (50% RR A1c 12 to 8)
  – Retinopathy (linear reduction with A1c)
  – Neuropathy
  – NNT (per UKPDS) was 19.6 patients to prevent one diabetes related endpoint at 10 years (with intensive therapy and average A1c of 7)
  – Benefits are independent of method, and UKPS summary “no firm conclusions regarding the optimal choice of therapy can be made at this time”

• Macro-vascular complications? probably negligible benefits
Next…BP=154/87…and he wants to go there
Tight blood pressure control in type 2 diabetes  Kaplan-Meier plot of the proportion of patients with type 2 diabetes with a clinical endpoint, fatal or nonfatal, according to the degree of blood pressure (BP) control in the UKPDS. The mean BP in the two groups was 144/82 and 154/87 mmHg, respectively. At eight to nine years, patients in the tight BP control group had a 24 percent reduction in diabetes-related endpoints, including microvascular disease (37 versus 49 percent, P = 0.0046). Redrawn from UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317:703.
Lower systolic pressure reduces complications in type 2 diabetes
Among 3642 patients with type 2 diabetes mellitus in the United Kingdom Prospective Diabetes Study (UKPDS), there was an inverse correlation between the updated mean systolic blood pressure and the aggregate end point for any complication related to diabetes (myocardial infarction, sudden death, angina, stroke, renal failure, lower extremity amputation or death from peripheral vascular disease, death from hyperglycemia or hypoglycemia, heart failure, vitreous hemorrhage, retinal photocoagulation, and cataract extraction). The lowest risk occurred at a systolic pressure below 120 mmHg. The values, adjusted for age, sex, and ethnic group, are expressed for white men aged 50 to 54 years at diagnosis with a mean duration of diabetes of ten years. (Data from Adler, Al, Stratton, IM, Neil, HA, et al, BMJ 2000; 321:412.)
HTN and DMII

• HTN, occurs just before, and is associated with microalbuminuria
• Associated with obesity
• Hyper-insulin state increases systolic BP
• Hyperglycemia leads to Na retention
• Increased arterial stiffness
• Treat early and treat aggressively
• Bottom line...get them below 130/80
Considerations…

- ALLHAT showed us that lisinopril, amlodipine, and chlorthalidone provided similar protection from coronary death and nonfatal AMI among DM patients.
- Thiazide outperformed ACEI and CaCB slightly.
- ACEI offer other advantages:
  - No adverse effect on lipids
  - May lower BS
  - May prevent DM (HOPE & LIFE trials)
  - Slow progression of nephropathy
  - May slow progress of retinopathy
  - Safe and well tolerated
  - Cheap
  - ARB’s work as well (new data)
- Look for reasons to use ACEI’s
HOPE Trial

Ramipril improves outcome in patients with diabetes Kaplan-Meier survival curves for 3755 patients with diabetes enrolled in the HOPE trials shows that ramipril significantly reduced both the incidence of any cardiovascular event (cardiovascular death, myocardial infarction, and stroke) compared to placebo (15.3 versus 19.8 percent) (panel A) and cardiovascular death (6.2 versus 9.7) (panel B). (Data from The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators, Lancet 2000; 355:253).
Soccer

Football  ITOOTR  OGSO  SOTG  LOTG  TRIAR
All Ball!  Assist  Attacking  Midfielder  Back
Back Defender  Ball!  Breakaway  Offensive
Central Defender  Charge  Defensive  Outside
Dribble  Drive  Drop  Ball  Far  and  Wide  Forward
Fullback  Get  It  Out  of  There!  Get  Square  Goal!
Goalie  Good  Save!  Hacking  Halfback  Hat  Trick
Header  Juggling  Keeper  Kickoff  Libero
Midfielder  Numbers  Down  Numbers  Up
Nutmeg  Penalty  Kick  Red  Card  Send  It!  Shoot
Starter  Stay  Wide!  Steal  Stopper  Striker
Sunday  Shot  Sweeper  Unlucky  Winger
Yellow  Card  The  Ball  Has  No  Lungs  Give  &  Go
The  Net  Knows  No  Gender  Deny,  Delay  &  Destroy
“You’ll  always  miss  100%  of  the  shots  you  don’t  take.”

Volleyball

Red  Card  Over  the  Net  Rotation  Beach  Serve
Power  Server  Co-Ed  Set  Ace  Setter  Assist
Side  Out  Attack  Six  Pack  Attacker  Spike
Backcourt  Striker  Back  Set  Strong  Side
Back  Row  Attack  Weak  Side  Beach  Dig  Wipe
Block  Yellow  Card  Bump  Campfire  Center  Line
Closing  the  Block  Cross  Court  Shot  Cut  Shot
Decoy  Deep  Set  Dig  Dink  Double  Block
Doubles  Down  Ball  Floater  Foul!  Free  Ball
Hit  Hitter  Isolation  Play  Jungle  Ball  Jump  Serve
Key  Kill  Line  Shot  Middle-Back  Middle-Up
Outside  Hitter  Overhand  Pass  Jed  Pancake
Penetration  Power  Alley
Quick  Set  Boom  Chuck

0011223344
5566778899
Lipids…

- ATPIII study declared DMII and previous MI as equal in risk for a macro-vascular event (CHD equivalent)
- Hyperglycemia leads to glycation of ApoB, increasing LDL $\frac{1}{2}$ life, which is taken up peripherally by macrophages. These foam cells collect in atherosclerotic plaque making it unstable and at risk of rupture
Lipids…

• The CARE, LIPID, and 4S Trials showed STATIN therapy decreased the risk of cardiovascular events (RR 0.76, 95 percent CI 0.59 to 0.93) with an absolute risk reduction of 7 percent. The number of patients needed to treat for benefit was 13 to 14.

• ADA, ATPIII, and Hrt Protection Study recommends LDL<100

• 2004 update adds recommendation to lower LDL 30% even if this is under 100

• ATP 2003 update recommends lowering LDL to <70 with “active CAD”

• UpToDate states…”we recommend an LDL goal of 80 in DM”

• Lower is better, diet goes without saying, start STATINS early, Niacin reasonable 2nd agent (but may increase BS initially)
What is next for our patient?
Next...“smoking has got to go before it smokes me!”
DM: “Smoking is bad for you” Why?

- Independent risk factor all-cause mortality
- Mortality increases with dose and duration
- Risk returns to baseline at 10 years
- Increases LDL, VLDL, and lowers HDL
- Makes insulin resistance worse
- Harder to control BS’s
- Makes neuropathy worse
- Cessation is the most beneficial intervention on survival outperforming any other single intervention
Increased cardiovascular risk in type 2 diabetes  Calculated effects of different interventions on coronary and total deaths in 1000 normal and 1000 men with type 2 diabetes aged 35 to 57 years without a history of myocardial infarction. Although risk was reduced by the therapeutic interventions (particularly cessation of smoking), there was a residual three to four fold increase in mortality in the diabetic men, due presumably to the effects of hyperglycemia or hyperinsulinemia. (Data from Yudkin, JS, BMJ 1993; 306:1313.)
RE: Micro-vascular disease,
What do you screen for in our patient?...and how?
Neuropathy - the foot exam

Testing sites for pressure sensation in evaluation of diabetic foot. The monofilament used to evaluate pressure sensation should be tested at each of the 12 sites shown, which represent the most common sites of ulcer formation. Failure to detect cutaneous pressure at any site indicates that the patient is at high risk for future ulceration.

Semmes-Weinstein 5.07 (10-g) monofilament
Retinopathy - referral annually

**Onset of retinopathy precedes diagnosis of type 2 diabetes**
Prevalence of retinopathy in relation to years after onset of diabetes among patients in southern Wisconsin (blue circles) and rural western Australia (red squares). At diagnosis (year zero), retinopathy was already present in 10 to 20 percent of patients. The lines extrapolate back to an estimated onset of retinopathy four to seven years before the clinical diagnosis was made. (Data from Harris, MI, Klein, R, Welborn, TA, Knuiman, MW, Diabetes Care 1992; 15:815.)

Why? Because laser therapy prevents visual loss.
Nephropathy-Microalbumin/Crt ratio

MA = 30 is micro-proteinuria, suggests nephropathy
- Confirm with 2\textsuperscript{nd} test
- Start ACEI or ARB
- Glucemic control

MA = 300 is macro-proteinuria
- Glycemic control
- Prep for dialysis
Top Priority for CRR in DM should be

1. Smoking cessation
2. ASA
3. BP
4. Lipids
5. Diet
6. Exercise
7. ACEI
How do you help patients participate, succeed, and then “maintain the gains”? 

- Self-management support 
- Collaborative goal setting 
- Knowledge/nutrition 
- Promote physical activity 
- Involve family 
- Problem solving 
- Depression scn and management 
- BBSWAR